New drug OK-1 tested in patients with Hard-to-Treat cancers
NCT ID NCT04928508
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study tests the safety of a new drug called OK-1 (SHetA2) in adults with advanced or recurrent solid tumors that have not responded to other treatments. About 50 participants will receive the drug to see what side effects occur and to find the best dose for future studies. The goal is to control the disease, not to cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Zinc-Based compound fight cancer?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can a new drug shrink Hard-to-Treat solid tumors?
- New imaging agent aims to light up hidden tumors
- Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
- New scan could reveal hidden cancer cells